Diplomat Pharmacy (DPLO) Misses Q3 EPS by 3c, Offers Guidance

Diplomat Pharmacy (NYSE: DPLO) reported Q3 EPS of $0.21, $0.03 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $1.18 billion versus the consensus estimate of $1.26 billion.

GUIDANCE:

Diplomat Pharmacy sees FY2016 EPS of $0.83-$0.87, versus the consensus of $0.93. Diplomat Pharmacy sees FY2016 revenue of $4.4-4.6 billion, versus the consensus of $4.67 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.

You May Also Be Interested In

• WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
• Sempra names new CFO and SoCalGas CEO amid infrastructure deal
• Everforth upsizes revolving credit facility to $600 million